Company ProfilePremium

XRF Scientific Limited

Company Profile Analysis

Ticker: XRF.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
XRF Scientific Limited - Company showcase

Year Founded & Workforce

1972

XRF Scientific Limited logo

XRF Scientific Limited Employee Contacts

7 verified contactsNames, job titles, seniority and locations

View Employee Contacts

XRF Scientific Limited Overview

XRF Scientific is a Perth-based, vertically integrated specialist in sample preparation for elemental analysis — the step that converts a raw ore, cement, steel or industrial sample into a homogeneous fused bead, pressed pellet or crushed aliquot that an XRF, ICP or combustion analyser can measure accurately. The company manufactures lithium borate fusion fluxes and laboratory chemicals (Consumables), automated fusion machines, furnaces, laboratory jaw crushers and analytical instruments (Capital Equipment), and platinum labware with an associated recycling service (Precious Metals). Its economic engine is a razor-and-blade model: a growing installed base of xrFuse fusion machines pulls through recurring flux sales and periodic platinum crucible recycling. Mining-sector sample testing remains the dominant demand driver, but management is deliberately broadening the instrument portfolio — Orbis crushers, xrTGA thermogravimetric analysers and, from April 2026, Bruker's former combustion gas analysis range — while expanding direct presence in India and the United States.


Company's own description

In its FY2026 Annual Report the company describes its principal activity as the manufacture and marketing of precious metal products, specialised chemicals and instruments for the scientific, analytical and mining industries, noting no significant change in the nature of activities during the year. Its standard corporate boilerplate (ASX announcements, 2026) states that XRF manufactures equipment and chemicals distributed to production mines, construction material companies and commercial analytical laboratories in Australia and overseas, used in the preparation of samples for analysis, with manufacturing, sales and support facilities in Australia, Europe, Canada and India, plus a global distributor network and representation in the United States, South America, Africa, the Middle East and Asia. Named blue-chip customers include BHP, Rio Tinto, Vale, South32, Glencore, Alcoa, Lafarge, Holcim, ArcelorMittal, CSIRO, Intertek, Bureau Veritas, SGS and ALS.

Revenue recognition (Note 1(e), FY2026): revenue is derived from manufacture and sale of chemicals, equipment and accessories, recognised at a point in time on delivery, plus service revenue from installation, maintenance and repair, some recognised over one- or two-year service contracts.

Revenue model mix

Revenue type (AUD Mn)FY2022FY2023FY2024FY2025FY2026
Sale of goods (A$m)39.2954.2958.3157.7162.56
Service revenue point in time (A$m)0.460.591.181.041.26
Service revenue over time (A$m)0.260.290.350.440.31
Interest income (A$m)0.000.090.280.260.27
Total revenue (A$m)40.0155.2660.1259.4564.40

Source: Note 5, FY2023, FY2025, FY2026 Annual Reports.

The business is overwhelmingly a product business (c.97.5% of external revenue in FY2026 from sale of goods). Services (installation, maintenance, repair) were c.2.5%. There is no subscription or licensing revenue. However, the economic character is more recurring than the product label suggests: consumable flux sales and platinum labware recycling are repeat purchases consumed in every analysis cycle. In 1H FY2023 management disclosed that ongoing spare parts and service revenue represented 27% of Capital Equipment revenue (Half-year presentation, Feb 2023). Consumables (A$18.1m FY2026) plus recycling-driven Precious Metals revenue imply that roughly half of group revenue is consumption-linked (analyst characterisation; recycling share of Precious Metals revenue is not separately disclosed).

Pricing mechanics. Precious Metals and Consumables both operate cost-plus or pass-through pricing on volatile inputs (platinum and lithium carbonate respectively). The FY2026 Annual Report notes that higher platinum prices increased customer prices for new products and recycling; the FY2025 report notes that falling lithium chemical prices reduced both selling prices and production costs. The company states in Note 2 that because customer commitments are at market rates, its commodity price exposure is immaterial. Revenue therefore moves with commodity prices while margin dollars are relatively insulated.

Value chain position

XRF sits in the pre-analytical segment of the analytical instrumentation value chain. Spectrometer OEMs (Thermo Fisher, Bruker, Malvern Panalytical, Rigaku, Hitachi) sell the measurement device; XRF supplies the consumables and equipment that prepare the specimen. Accuracy of borate fusion is a pre-requisite for high-precision XRF analysis of ores, cement and slags, making fluxes and platinumware critical-path inputs with low cost relative to the value of the analytical result. The company is vertically integrated: it fabricates platinum labware (Melbourne plant; Germany), blends and fuses lithium borate fluxes (Perth), designs and assembles fusion machines (Perth; xrTGA in Melbourne) and, through Orbis, laboratory crushers. The April 2026 CGA acquisition moves XRF one step further down the chain into the measurement layer itself (CS/OHN analysers).

Customer types and end-markets

Customer typeDescriptionEvidence
Commercial analytical laboratoriesGlobal testing houses (ALS, SGS, Bureau Veritas, Intertek) processing exploration and grade-control samplesNamed customer list, ASX boilerplate
Production mines (on-site labs)Iron ore, bauxite, nickel, copper, gold, lithium operationsFY2023–FY2026 operating commentary
Construction materialsCement and aggregates producers (Lafarge, Holcim)ASX boilerplate
Metals and steelArcelorMittal; iron, steel, aluminium, copper producersASX boilerplate; CGA application list
Industrial / researchGlass, ceramics, chemicals, petrochemicals, CSIRO, nuclear materials, rare-earth magnets, additive manufacturingCGA acquisition announcement (Apr 2026)
New TGA verticalsFood, plastics, agricultural products quality controlFY2023 Annual Report (xrTGA launch)

Independent characterisation

XRF is best understood as a mining-cycle-exposed, consumables-anchored niche industrial with an increasingly diversified instrument arm. Its moat rests on (i) installed-base lock-in (xrFuse machines specify XRF fluxes and platinumware), (ii) a claimed 50%+ share of the global fusion flux market (Morgans profile), (iii) in-house platinum fabrication and recycling capability that few competitors replicate at its scale in the Southern Hemisphere, and (iv) a capital-light, net-cash balance sheet funding bolt-on M&A. The principal vulnerabilities are concentration on mining sample volumes, small scale against diversified multinationals, and lumpy capital-equipment demand.

Strategy

Stated strategy (FY2026 Annual Report and FY2026 results)

The FY2026 Directors' Report states the group's objectives are to increase profitability and market capitalisation, with strategies comprising geographic expansion initiatives, new product development, and acquisition of complementary laboratory product manufacturing or supply companies. Recurring themes across FY2025–FY2026 disclosure:

  1. International sales growth — described as a key focus, to be accelerated through new international offices and the CGA acquisition.

  2. Cross-selling — customers increasingly buying multiple products across the range (fluxes, machines, platinumware, crushers, instruments).

  3. Installed base monetisation — growing machine base generating recurring consumables, platinum recycling, spare parts and service revenue.

  4. New products — xrTGA, next-generation xrFuse, Orbis line extensions, gold-sector products, and at least six new machines in advanced development.

  5. Bolt-on M&A in adjacent sectors — value-accretive acquisitions funded from cash.

Initiatives register (last 24 months)

DateInitiativeTypeDetail / targetStatus
Jul 2024Orbis 100% ownershipM&ARemaining 50% for A$3.9m upfront plus earn-out (A$0.8m settled in shares FY2026)Complete
Dec 2024Labfit acquisitionM&AA$1.2m; CS and pH analysers, weighing systemsIntegrated Mar 2025 qtr
FY2025STG Mining Supplies distribution (Americas)ChannelSix countries; became leading external Orbis distributorActive
FY2025–FY2026Melbourne platinum automationOperationalAutomation to lower cost and improve production technologyOngoing
Sep 2025 qtrNext-gen xrFuse 1 and 2ProductLaunched; positive receptionLaunched
Feb 2026India direct officeGeographicFive staff; transition from distributor modelProfitable Sep 2026 qtr
FY2026USA direct officeGeographicOpened; supports Orbis, CGA, consumablesRamping
Apr 2026CGA acquisition from BrukerM&A / productUS$4m upfront + up to US$1m earn-outIntegration; production in Perth from Dec 2026 qtr
Sep 2026 qtrOrbis OM25 and Standalone RSD/LSDProductSmaller-lab crusher; standalone dividersReleased
Sep 2026 qtrClosure of platinum inventory leaseBalance sheetOff-balance-sheet lease no longer requiredComplete
FY2027Growth prioritiesStrategyRamp India and US offices; grow Orbis and xrTGA; launch CGA instruments and consumables; gold-sector product developmentGuided

Cost programmes and ESG commitments

No formal cost-reduction programme with quantified targets has been announced. The company references ongoing cost control and productivity improvements (FY2025 Chairman's letter) and automation at the Melbourne plant (FY2026). No quantified ESG or emissions targets have been published.

Medium-term targets and guidance

The company does not publish quantitative financial guidance; the FY2026 Annual Report states that likely results are not disclosed to avoid commercial prejudice. Qualitative guidance (13 October 2026): the December 2026 quarter is expected to be another strong period, with incremental CGA instrument revenue and significant Orbis growth. CGA revenue is expected from Q2 FY2027 once production has transferred to Perth.

Products & Services

Pricing for individual products is not publicly disclosed. Precious Metals and Consumables pricing broadly follows input-cost pass-through (platinum, lithium) per annual report commentary.

Consumables segment

Product / brandDescription & capabilitiesTarget customerLaunch / latest versionNotes
Lithium borate fusion fluxesPre-fused lithium tetraborate / metaborate blends (with optional integrated non-wetting agents and oxidisers) used to dissolve oxide samples into homogeneous glass beads for XRF or into solution for ICPMining labs, commercial labs, cement, steelOrigin 1972; continuously developedCore franchise; company cited as holding 50%+ of global fusion flux market (Morgans)
Patented copper-analysis fluxSpecial flux formulation for copper ore/concentrate analysisCopper producers and labsUsed by Australian customers; first international sale FY2026Patented (FY2026 Annual Report)
xr-Tab binder tabletsBinder tablets for pressed-pellet sample preparationXRF labs using pressed powdersLaunched FY2023FY2023 Annual Report
Laboratory chemicals and suppliesAncillary reagents, releasing agents, oxidisers, calibration materialsAnalytical laboratoriesOngoingProduct catalogue (Jan 2024)
Calibration standards and drift monitorsCalibration sets, XRF drift monitors, customised fused beadsXRF laboratoriesOngoingProduct catalogue
Application kits and method developmentSample preparation and application kits for XRF and ICP; method development servicesLabs establishing new methodsOngoingProduct catalogue; David Brown consultancy (technical services)

Capital Equipment segment

Product / brandDescription & capabilitiesTarget customerLaunch / latest versionNotes
xrFuse fusion machines (incl. xrFuse 1, xrFuse 2 and multi-position models)Electric automated fusion instruments producing glass beads for XRF and solutions for ICPMining, cement, steel, commercial labsNext-generation xrFuse 1 and 2 launched FY2026Installed base drives flux and platinumware pull-through
High-temperature furnacesTest and production furnaces, including loss-on-ignition applicationsLabs and industrial usersOngoingSegment description FY2023
xrTGAThermogravimetric analyser — heats samples to set temperatures while measuring mass change; applications in iron ore, bauxite, nickel, cement, and new verticals (food, plastics, agriculture)Mining and industrial QC labsLaunched June 2023; first deliveries Dec 2023 quarterManufactured in Melbourne; A$1m sales in FY2026
Orbis laboratory jaw crushersLaboratory jaw crushers with patented component enabling large feed (up to c.110 mm) to be crushed to c.2 mm in a single passCommercial labs, mine-site labs, gold sectorOrbis founded 2014; OM25 compact crusher released Sep 2026 quarterIncreasingly integrated into robotic sample preparation cells
Orbis Standalone RSD / LSDRotary and linear sample dividers for representative sub-samplingCommercial and mine labsReleased Sep 2026 quarterASX 13 Oct 2026
Labfit carbon-sulphur analysersElemental analysis of carbon and sulphur in mining and industrial samplesMining and industrial labsAcquired Dec 2024FY2025 Annual Report
Labfit pH analysersMeasurement of acidity/alkalinity in water, soil and other samplesEnvironmental, agricultural, industrial labsAcquired Dec 2024FY2025 Annual Report
Labfit laboratory weighing systemsAutomated laboratory weighingLabsAcquired Dec 2024FY2025 Annual Report
CGA CS/OHN analysers (ex-Bruker) — four instruments incl. "G4 Icarus"Rapid elemental analysis of carbon, sulfur, oxygen, hydrogen and nitrogen using three technologies: hot extraction, inert gas fusion, and combustion by induction heatingNuclear energy materials, rare-earth magnets, powder metallurgy/additive manufacturing, welding, ores and minerals, glass, ceramics, cement, iron, steel, cobalt, nickel, copper, aluminiumAcquired Apr 2026; Perth production expected to commence Dec 2026 quarterProduct names such as G4 Icarus transferred and rebranded XRF Scientific; identities of the other three instruments not specified in XRF disclosure
Other sample-preparation equipmentBench-top and laboratory equipment, drying ovens, general lab equipmentLabsOngoingProduct catalogue
Spare parts and serviceInstallation, maintenance contracts (1–2 years), repairsInstalled baseOngoingNote 1(e); service revenue A$1.57m FY2026
Pipeline"At least six new machines in advanced stages of development" for release through FY2027 and beyond; gold-sector product developmentVariousFY2027+FY2026 Annual Report; FY2026 results

Precious Metals segment

Product / serviceDescriptionTarget customerNotes
Platinum labware — cruciblesPt/Au (typically 95/5) crucibles for fusionXRF/ICP labsOften sold alongside new fusion machines
Platinum labware — moulds / casting dishesMoulds for casting fused glass beadsXRF labsPrecision fabrication in Melbourne
Labware recycling / refabricationSpent platinumware returned, refined and refabricated; recurring with sample volumesMining and commercial labsDescribed as at "positive levels" in Sep 2026 quarter
Industrial platinum alloy productsCustomised platinum alloy products for industrial users (e.g., European industrial customers served from Germany)Industrial manufacturersGermany office revenue A$7.3m FY2023
Metal salesOccasional sale of metal (e.g., A$2.05m one-off sale in Sep 2026 quarter on closure of a platinum inventory lease, margin A$0.1m)Lessors / counterpartiesNon-recurring

Financial Narrative

All figures A$m, fiscal years ended 30 June, from audited annual reports (FY2023 report for FY2022–FY2023; FY2025 report for FY2024–FY2025; FY2026 report for FY2026). Ratios derived.

Income statement

Notes: FY2026 adjusted PBT excludes A$0.69m of CGA acquisition costs and India/USA office set-up costs. Discrepancy flag: the FY2025 Directors' Report narrative states NPAT attributable to members of A$10,337,596 in one sentence and A$10,383,453 in the results table; the audited income statement confirms A$10,383,453 attributable and A$10,337,596 total NPAT (the NCI absorbed a A$45,857 loss). FY2023 PBT is A$11.79m statutory; the results release quoted A$11.1m because it was presented net of the Orbis non-controlling interest.

Margins and growth (derived)

FY2022 revenue growth calculated against FY2021 total revenue of A$31.29m (sales) as reported in FY2023 Annual Report charts; FY2022 NPAT growth against FY2021 NPAT of A$5.13m.

Compound growth (derived): FY2022–FY2026 total revenue CAGR 12.6%; sales revenue CAGR 12.5%; NPAT attributable CAGR 14.6%; EPS CAGR 13.2%; DPS CAGR 15.8%; EBITDA CAGR 15.7%.

Commentary. The five-year profile has two distinct phases. FY2022–FY2023 was volume-led hypergrowth: revenue rose 38% in FY2023 on record fusion-machine orders, rising lithium-driven flux prices and Orbis consolidation, while gross margin actually compressed (to 41.6%) as pass-through pricing inflated revenue faster than margin dollars. FY2024–FY2026 was margin-led: revenue grew only 7% cumulatively over FY2024–FY2026's first two years while gross margin expanded c.770bp to 49.3% in FY2026, driven by (i) falling lithium input costs reducing both price and cost (mechanically lifting percentage margin), (ii) product mix toward higher-margin Orbis and instruments, and (iii) productivity gains in the Melbourne platinum plant. The FY2026 inflection is that operating leverage stalled: gross profit rose A$2.9m but administration, occupancy and other expenses rose A$2.3m combined, reflecting new offices, CGA integration and a A$0.9m rise in employee benefits expense. Statutory NPAT therefore grew only 1%, though adjusted PBT grew 10%. The effective tax rate also rose to 31.8% on non-deductible acquisition costs and sundry items.

Balance sheet

Negative net debt denotes a net cash position. Borrowings at 30 June 2026 consist of a property loan (A$0.94m) for the Melbourne platinum factory; remaining platinum loans of A$0.7m were repaid early in FY2026 owing to high interest cost.

Commentary. The balance sheet is conservative and has strengthened every year except FY2026, when cash fell A$2.8m because the A$5.6m CGA cash consideration was funded internally. Inventory is the dominant asset (27% of total assets in FY2026) and grew A$2.2m in FY2026, primarily raw materials and spare parts (A$11.0m vs A$8.9m), consistent with CGA stock (A$0.7m acquired) and new-product build. Intangibles rose A$6.6m on CGA (goodwill A$4.40m; acquired development assets A$1.79m). A A$1.4m earn-out provision was recognised. Equity grew A$6.2m despite A$6.4m of declared dividends, aided by DRP issuance and the A$0.8m Orbis earn-out settled entirely in shares.

Cash flow

Commentary. Cash conversion has normalised to around 1.0x NPAT after the FY2022 trough (0.52x), when rising lithium prices and machine build absorbed working capital. Capex remains modest at 2.6–4.0% of revenue, confirming a capital-light model. Capitalised R&D stepped up in FY2025–FY2026 (A$0.40m to A$0.76m), aligned with the six-machine development pipeline. FCF after leases of A$8.0m in FY2026 covered cash dividends (A$5.0m) 1.6x; the remaining cash plus opening balance funded CGA. No buybacks have been undertaken; the DRP is the preferred capital-retention mechanism.

Returns, leverage and efficiency ratios (derived)

Invested capital = total equity + borrowings + lease liabilities − cash. NOPAT = EBIT × (1 − effective tax rate). DIO/DPO computed on cost of sales; payables include other payables, so DPO is approximate.

Commentary. Returns are solid rather than spectacular for a niche industrial, peaking at c.20% ROIC in FY2024–FY2025. The FY2026 dip to 17.5% reflects the A$5.6m CGA investment entering invested capital before generating revenue (expected from Q2 FY2027). The standout weakness is the very long cash conversion cycle (c.200–250 days), structurally driven by precious-metal inventory (platinum held for fabrication) and a broad spare-parts and raw-materials holding across many SKUs. The progressive replacement of leased platinum with owned metal over the past decade (culminating in closure of the last off-balance-sheet lease in the September 2026 quarter) improves resilience but increases inventory days. Leverage is negligible and the business is effectively ungeared.

Quarterly trading cadence (unaudited, from quarterly trading reports)

Q2FY25 and Q4FY25 revenue derived by subtraction from half-year and full-year totals. Q4FY26 PBT shown statutory (derived: FY26 PBT less 9M PBT); company-reported adjusted Q4FY26 PBT was A$4.7m. Q1FY27 includes a one-off A$2.05m metal sale (margin A$0.1m); excluding it, revenue grew 25%.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Income Statement and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Total revenue (AUD Mn)

40.0155.2660.1259.4564.40

Sales revenue — external customers (AUD Mn)

40.0155.1759.8459.1964.13

Cost of sales (AUD Mn)

22.6932.2833.5730.6532.68

Gross profit (AUD Mn)

17.3222.9826.5528.7931.72

Administration expenses (AUD Mn)

7.769.1710.8611.8413.18

Occupancy expenses (AUD Mn)

0.770.970.951.091.26

Other expenses (AUD Mn)

0.560.881.001.051.83

Finance costs (AUD Mn)

0.070.220.290.260.13

EBIT — derived (AUD Mn)

8.2611.9213.4714.5815.23

Depreciation and amortisation (AUD Mn)

1.181.201.571.691.71

EBITDA — derived (AUD Mn)

9.4413.1315.0416.2716.94

Profit before tax (AUD Mn)

8.1911.7913.4614.5915.37

Adjusted PBT — company definition (AUD Mn)

8.1911.7913.4614.5916.06

Income tax expense (AUD Mn)

2.103.613.974.254.88

Net profit after tax — total (AUD Mn)

6.098.189.5010.3410.49

NPAT attributable to members (AUD Mn)

6.087.698.8910.3810.49

EPS basic (A$ cents)

4.55.66.47.47.4

EPS diluted (A$ cents)

4.55.66.47.47.3

Dividends declared per share (A$ cents)

2.53.33.94.54.5

Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Gross margin (%)

43.341.644.248.449.3

EBIT (operating) margin (%)

20.621.622.424.523.6

EBITDA margin (%)

23.623.825.027.426.3

PBT margin (%)

20.521.322.424.523.9

Net margin attributable (%)

15.213.914.817.516.3

Effective tax rate (%)

25.630.629.529.131.8

Total revenue growth (%)

27.938.18.8-1.18.3

NPAT attributable growth (%)

18.626.315.616.91.0

Dividend payout ratio on EPS (%)

55.658.960.960.860.8

Balance Sheet

MetricFY2022FY2023FY2024FY2025FY2026

Total assets (AUD Mn)

55.5665.5568.2372.7978.65

Cash and cash equivalents (AUD Mn)

6.6510.4012.0512.239.46

Trade and other receivables (AUD Mn)

6.238.639.5210.289.74

Inventories (AUD Mn)

15.5216.8817.0218.8321.02

of which precious metals owned (AUD Mn)

3.335.30

not captured

4.645.17

of which platinum on loan (AUD Mn)

2.641.52

not captured

0.740.00

Property plant and equipment incl. ROU (AUD Mn)

8.6610.4110.8311.7212.19

Goodwill and intangibles (AUD Mn)

16.9516.8716.6217.2923.92

of which goodwill (AUD Mn)

not captured

not captured

15.4215.8420.12

Short-term borrowings (AUD Mn)

1.300.781.620.170.17

Long-term borrowings (AUD Mn)

1.461.290.000.940.77

Total borrowings (AUD Mn)

2.772.071.621.120.94

Lease liabilities current plus non-current (AUD Mn)

0.752.241.761.761.40

Net debt excl. leases — derived (AUD Mn)

-3.88-8.33-10.43-11.12-8.52

Net debt incl. leases — derived (AUD Mn)

-3.13-6.09-8.67-9.35-7.12

Total current assets (AUD Mn)

28.9136.5339.2041.9640.95

Total current liabilities (AUD Mn)

9.6611.6210.459.548.34

Working capital — derived (AUD Mn)

19.2624.9128.7532.4332.61

Total liabilities (AUD Mn)

12.2115.9712.6912.6212.26

Total equity (AUD Mn)

43.3549.5855.5460.1766.40

Cash Flow and Financial Ratios (x)

MetricFY2022FY2023FY2024FY2025FY2026

Operating cash flow (AUD Mn)

3.158.428.0910.1411.39

Payments for PP&E (AUD Mn)

0.370.761.611.751.70

Capitalised R&D payments (AUD Mn)

0.150.020.030.400.76

Other intangibles (AUD Mn)

0.000.000.000.000.13

Total capex incl. capitalised R&D (AUD Mn)

0.520.781.642.152.59

Free cash flow — derived OCF less total capex (AUD Mn)

2.637.636.457.998.80

Lease principal payments (AUD Mn)

0.470.510.750.770.80

FCF after leases — derived (AUD Mn)

2.167.135.707.228.00

Business acquisitions net of cash (AUD Mn)

0.600.000.000.955.60

Transactions with NCI — Orbis buyout (AUD Mn)

0.000.000.001.960.00

Cash dividends paid to members (AUD Mn)

2.132.683.604.125.02

Dividends declared incl. DRP (AUD Mn)

2.703.404.525.446.41

Share buybacks (AUD Mn)

0.000.000.000.000.00

OCF to NPAT attributable conversion (x)

0.521.100.910.981.09

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2022FY2023FY2024FY2025FY2026

ROE on closing equity (%)

14.015.516.017.315.8

ROA on closing assets (%)

10.911.713.014.313.3

ROIC — NOPAT over invested capital (%)

15.319.020.320.317.5

Current ratio (x)

2.993.143.754.404.91

Debt incl. leases to equity (x)

0.080.090.060.050.04

Net debt incl. leases to EBITDA (x)

-0.33-0.46-0.58-0.57-0.42

Interest coverage EBIT over finance costs (x)

121544757116

Asset turnover revenue over closing assets (x)

0.720.840.880.820.82

Days sales outstanding (days)

5757586355

Days inventory outstanding (days)

250191185224235

Days payables outstanding (days)

5045454840

Cash conversion cycle (days)

257203198239250

Income Statement

Quarter metricQ1FY25Q2FY25Q3FY25Q4FY25Q1FY26Q2FY26Q3FY26Q4FY26Q1FY27

Revenue (AUD Mn)

13.115.613.916.815.316.015.817.221.1

Profit before tax (AUD Mn)

3.23.73.44.33.44.13.74.24.4

Region revenue (AUD Mn)

Region revenue (AUD Mn)FY2022FY2023FY2024FY2025FY2026

Australia-invoiced (AUD Mn)

25.5837.3243.1441.2343.67

Canada-invoiced (AUD Mn)

4.205.075.565.446.46

Europe-invoiced (AUD Mn)

10.2212.7911.1312.5214.01

Total (AUD Mn)

40.0155.1759.8459.1964.13

Region growth and share (%)

Region growth and share (%)FY2023FY2024FY2025FY2026

Australia growth (%)

45.915.6-4.45.9

Canada growth (%)

20.69.8-2.318.7

Europe growth (%)

25.1-13.012.411.9

Australia share (%)

67.672.169.768.1

Canada share (%)

9.29.39.210.1

Europe share (%)

23.218.621.121.8

FY2026 Segment × Region Details

FY2026 segment × region (AUD Mn)AustraliaCanadaEuropeTotal

Capital Equipment

18.421.144.4824.04

Precious Metals

10.734.077.2422.04

Consumables

14.521.252.2818.05

Total

43.676.4614.0164.13

Revenue by Region

Capital Equipment by region (AUD Mn)FY2022FY2023FY2024FY2025

Australia (AUD Mn)

7.1213.9215.6915.80

Canada (AUD Mn)

0.390.770.810.63

Europe (AUD Mn)

2.692.864.064.41

Revenue by Region by Precious Metals by Region

Precious Metals by region (AUD Mn)FY2022FY2023FY2024FY2025

Australia (AUD Mn)

8.159.3211.779.96

Canada (AUD Mn)

3.103.153.763.41

Europe (AUD Mn)

6.458.224.925.72

Revenue by Region by Consumables by Region

Consumables by region (AUD Mn)FY2022FY2023FY2024FY2025

Australia (AUD Mn)

10.3114.0815.6815.48

Canada (AUD Mn)

0.711.141.001.40

Europe (AUD Mn)

1.081.712.142.39

Share price at 30 June (AUD)

Share price at 30 June (AUD)FY2022FY2023FY2024FY2025FY2026

Closing price (AUD)

0.571.171.3451.841.73

Market capitalisation (AUD Mn)

77.46160.35185.76258.59247.46

Return measure (approx., price only)

Return measure (approx., price only)Value

Current price (14–15 Oct 2026)

A$1.87–1.92

Calendar 2026 YTD (from A$2.06 opening)

c.-9% to -7%

1-year

c.-5% to -15% (aggregators reported -11% to -15% in Aug–Sep 2026; partially reversed by the 13 Oct 2026 rally)

3-year (vs 30 Jun 2023 A$1.17)

c.+60%

5-year (vs 30 Jun 2021 A$0.475)

c.+295%

52-week range (as of Aug 2026)

A$1.60 – A$2.40

Since IPO (A$0.20, Oct 2006)

c.+840%

Valuation Multiples

MultipleXRF ScientificBasis

Market capitalisation

c.A$269m

143.7m shares × A$1.87

Enterprise value

c.A$262m

Market cap − cash A$9.46m + borrowings A$0.94m + leases A$1.40m

P/E (trailing)

c.25.3x

A$1.87 ÷ 7.4c EPS

EV/EBITDA (trailing)

c.15.5x

A$262m ÷ A$16.94m

EV/Sales (trailing)

c.4.1x

A$262m ÷ A$64.4m

P/B

c.4.0x

A$269m ÷ A$66.4m equity

Dividend yield (fully franked)

c.2.4% (c.3.4% grossed-up)

4.5c ÷ A$1.87

Analyst Ratings & Targets

BrokerRatingTarget (AUD)Date

Canaccord Genuity

Buy

2.30

19 Feb 2026 (from 2.35, Oct 2025)

Dividend (A$ cents per share)

Dividend (A$ cents per share)FY2022FY2023FY2024FY2025FY2026

Final dividend declared (A$ cents)

2.53.33.94.54.5

Franking (%)

100100100100100

Analyst Conclusions

Management guidance

No quantitative guidance is provided. Qualitative outlook (13 October 2026): the December 2026 quarter is expected to be strong, supported by new CGA instrument revenue and significant Orbis growth. FY2027 priorities (FY2026 results): ramp India and USA offices, grow Orbis and xrTGA, launch CGA instruments and consumables, develop gold-sector products, and pursue complementary acquisitions.

Consensus expectations

Detailed consensus is not publicly available. Aggregator summaries cite c.10% p.a. revenue growth and c.13% p.a. earnings growth. Analyst indicative frame (derived, not guidance): the September 2026 quarter run-rate (A$19.1m ex one-off sale) plus a full contribution from CGA (US$5.3m historical revenue ≈ A$8m) suggests FY2027 revenue potential in the low-to-mid A$70m range if Consumables recovery and Orbis growth persist; this should be treated as scenario analysis, not a forecast.

Bull case

  1. Portfolio step-change into instruments: CGA adds c.US$5.3m of revenue acquired at c.0.75x sales, while xrTGA (A$1m FY2026, repeat orders) and Orbis (+66% in Sep 2026 quarter) give Capital Equipment multiple independent growth vectors beyond fusion machines.

  2. Operating leverage on new offices: FY2026 absorbed A$0.69m of one-off acquisition/start-up costs and higher overheads; with India already profitable, FY2027 should see adjusted-to-statutory convergence and margin recovery, lifting EPS growth above revenue growth.

  3. Cyclical tailwind with balance-sheet optionality: strong gold and copper prices, rising exploration financing and lab automation support sample volumes, while a net-cash balance sheet supports further accretive bolt-ons.

Bear case

  1. Mining-cycle exposure: roughly two-thirds of invoicing is from Australia and demand is dominated by mining; a downturn in exploration or grade-control testing would hit both consumables and capital equipment simultaneously.

  2. Stalled profit growth and rich multiple: statutory NPAT grew just 1% in FY2026, Consumables revenue fell 6%, and the dividend was held flat, yet the stock trades at c.25x trailing earnings and c.15.5x EV/EBITDA — demanding for a A$64m-revenue cyclical industrial with thin liquidity.

  3. Execution risk in CS/OHN: transferring CGA production from Germany to Perth and competing against LECO and Eltra is a materially harder market than fusion consumables; the acquired business was non-core and sub-scale at Bruker.

Catalysts and monitorables (next 12 months)

TimingCatalyst / monitorable
Late Oct/Nov 20262026 AGM — board renewal signals, remuneration vote
Dec 2026 quarterFirst CGA instruments produced in Perth; Orbis growth
Jan 2027December 2026 quarterly trading report
Feb 20271H FY2027 results — CGA contribution, adjusted vs statutory margins, Consumables recovery
Apr 2027March 2027 quarterly trading report
Aug 2027FY2027 results; dividend growth resumption
OngoingPlatinum and lithium prices; gold price and exploration financing; AUD/USD/EUR; new-machine launches from the six-product pipeline; further bolt-on M&A; board renewal and diversity; India and USA office profitability

Analyst verdict

XRF Scientific is a high-quality micro-to-small-cap industrial that has quietly built a defensible niche at the unglamorous but essential front end of elemental analysis. Over FY2022–FY2026 it compounded attributable earnings at roughly 15% per annum, expanded gross margin to almost 50%, sustained ROIC near 20% and funded every acquisition from internal cash while paying fully franked dividends. The razor-and-blade structure — machines pulling through flux and platinumware — is genuine and is reflected in Consumables' durable 37–38% PBT margins.

FY2026 was a transition year. Revenue reached a record A$64.4m, but statutory profit was flat as the company invested in India, the United States and the Bruker CGA acquisition. The September 2026 quarter suggests that investment is beginning to pay: underlying revenue grew roughly 25%, Consumables rebounded 27%, Orbis grew 66%, and India turned profitable almost immediately. If CGA production transfers smoothly to Perth in the December quarter, FY2027 should combine revenue growth from three distinct instrument lines with a reversal of FY2026's one-off cost drag.

The principal debates are cyclicality and valuation. The business remains tied to mining sample volumes, its disclosure is thin, governance is concentrated around long-tenured directors and a founder with related-party arrangements, and liquidity is limited. At c.25x trailing earnings the shares already discount a return to double-digit EPS growth.

On balance, the evidence supports a constructive but disciplined view: XRF is a structurally improving, cash-generative niche leader whose near-term catalysts (CGA launch, Orbis momentum, India/US ramp) are tangible and observable quarter by quarter. Investors should underwrite the story on delivered CGA revenue and Consumables stability through 1H FY2027, and treat any renewed mining-volume weakness or integration slippage as the key signals that the premium multiple is not justified.


All figures are sourced from XRF Scientific's audited annual reports (FY2023, FY2025, FY2026), ASX announcements through 13 October 2026, and identified secondary sources.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleAppointed / tenureQualificationsPrior / other rolesShareholding (30 Jun 2026)Independence (analyst view)

Fred Grimwade

Non-Executive Chairman; Chair Remuneration Committee; member Audit & Governance

Director 1 May 2012 (14 yrs); Chairman since 29 Oct 2018

BCom, LLB, MBA; FGIA; FAICD; FCSI

Principal & Director, Fawkner Capital; Director, Regal Cream Products (Bulla) from Dec 2025; NED Australian United Investment Co (since Mar 2014); former Chair CPT Global (to Nov 2023), former NED Select Harvests (to Feb 2023); prior GM roles at Colonial Agricultural Co, Colonial Group, Western Mining Corp, Goldman Sachs

563,527 shares

Classified independent by tenure test caveat (>10 years)

David Brown

Non-Executive Director; technical consultant to XRF Chemicals

7 Jun 2004 (22 yrs)

BSc, BEc

Founder of XRF flux technology (1972); former Chief Chemist, Swan Brewery; former Chairman, Scientific Industries Council of WA

8,224,200 shares (c.5.7%)

Not independent (founder, substantial holder, paid consultant, landlord)

David Kiggins

Non-Executive Director; Chair Audit & Governance; member Remuneration

1 May 2012 (14 yrs)

BSc (Hons); FCA (ICAEW); FCIS; MAICD

CFO, Sadleirs; former CFO Stealth Global and Heliwest; former FD Global Construction Services; former GM Bus Dev Automotive Holdings Group; Arthur Andersen

217,181 shares

Independent subject to >10-year tenure caveat

Vance Stazzonelli

Managing Director; Joint Company Secretary

MD 22 Feb 2018; CEO Aug 2012; joined Oct 2009

BCom (Professional Accounting); CPA

XRF CFO (2009), COO (2011), CEO (2012)

1,240,000 shares; 547,375 performance rights

Executive

Executive Leadership Team

NameRoleTenureQualifications

Vance Stazzonelli

Managing Director

Since 2009 (MD 2018)

BCom, CPA

Andrew Watson

Chief Financial Officer; Joint Company Secretary

Joined Aug 2012; Joint CoSec Aug 2013

BCom; CA (CA ANZ); Grad Dip Applied Corporate Governance

Brad Hunting

Co-founder and General Manager, Orbis Mining (non-KMP)

Orbis founder 2014

—

Sanjay Mitra

Country Manager, India (non-KMP)

From Feb 2026

—

“—” = not publicly disclosed.

Directors' Remuneration

KMP FY2026 (AUD)Cash salaryCash bonusOtherSuperLSLShare-based (LTI)Total

Fred Grimwade

108,4820013,01800121,500

David Brown

65,6250255,5207,87500329,020

David Kiggins

75,089009,0110084,100

Vance Stazzonelli

448,200110,200030,54012,905170,201772,046

Andrew Watson

289,00044,64323,23142,7056,44367,202473,224

Directors' Remuneration (Annual)

Total remuneration (AUD)FY2022FY2023FY2024FY2025FY2026

Vance Stazzonelli total (AUD)

408,700774,385722,314811,294772,046

Andrew Watson total (AUD)

248,996403,943470,246475,264473,224

All KMP total (AUD)

1,060,7081,633,4051,684,0411,797,7001,779,890

Major Shareholders

HolderSharesStake (%)Source / date

David Brown (founder director)

8,224,200

c.5.7

FY2026 Annual Report (30 Jun 2026)

Michael Korber

8,611,3216.13

Substantial holder notice (Feb 2025: reduced from 7.58% after selling 2,931,201 shares at c.A$1.61)

Evelin Investments Pty Ltd

7,315,2165.21

Aggregator data (2025)

Charles Goode

3,000,0002.14

Aggregator data (2025)

Great Western Capital Pty Ltd

2,939,3742.09

Aggregator data (2025)

Stephen Prossor

2,669,7681.90

Aggregator data (2025)

Mandel Pty Ltd

2,364,9991.68

Aggregator data (2025)

Vance Stazzonelli

1,240,000

c.0.9

FY2026 Annual Report

Remaining top-10 holders

not captured

not captured

—

Competitive Landscape

Competitors by Segment

SegmentCompetitorOwnershipOverlapRelative positioning

Fusion fluxes and fusion machines

Malvern Panalytical (incl. Claisse fusion brand)

Spectris plc (agreed takeover by KKR in 2025; status should be verified)

Fusion machines, fluxes, XRF spectrometers

Global leader in XRF instrumentation; bundled solutions; much larger scale

Fusion machines

Katanax

—

Electric fusion machines

Niche competitor in electric fusion

Fluxes and sample-prep consumables

Fluxana (Germany)

Private

Fluxes, standards

European niche

Fusion and pressing equipment

Herzog

—

Automated sample preparation

Strong in steel/cement automation

Fusion, pressing, consumables

SPEX SamplePrep

Private (US)

Fusion fluxers, mills, presses

Strong US presence

Platinum labware

Heraeus

Private (Germany)

Platinum crucibles and moulds

Global precious metals major

Platinum labware

Johnson Matthey

LSE-listed

Platinum fabrication

Large precious metals group

Platinum labware

Furuya Metal

Tokyo-listed

Platinum group metal products

Asian presence

Laboratory crushers

Rocklabs

Scott Technology (NZX)

Lab jaw crushers, pulverisers

Direct Orbis competitor in mining labs

Laboratory crushers

FLSmidth (Essa)

Nasdaq Copenhagen-listed

Lab crushers, sample prep systems

Large mining OEM

Laboratory crushers and mills

Retsch

Verder Scientific (private)

Crushers, mills

Broad lab sample-prep range

CS/OHN analysers

LECO

Private (US)

Combustion and inert-gas fusion analysers; TGA

Global leader in CS/OHN

CS/OHN analysers

Eltra

Verder Scientific (private)

CS/OHN analysers

Strong European competitor

CS/OHN analysers

Horiba

Tokyo-listed

EMIA/EMGA analysers

Strong in Asian steel

CS/OHN and elemental

Elementar

Private (Germany)

Elemental analysers

Adjacent

Thermogravimetric analysis

Mettler-Toledo; TA Instruments (Waters); Netzsch; LECO

Listed/private

TGA instruments

Broad thermal-analysis incumbents; xrTGA targets mining/industrial QC niche

Peer Comparison FY2026

MetricXRF Scientific FY2026Bruker Corp FY2024Thermo Fisher FY2024Spectris FY2024

Revenue

A$64.4m

c.US$3.4bn

c.US$42.9bn

c.£1.3bn

Revenue growth

8.3%———

Operating margin

23.6% (EBIT, derived)

———

R&D intensity

≥1.2% (capitalised only; total not disclosed)

———

Relationship to XRF

—

Seller of CGA; XRF partner; XRF spectrometer OEM

XRF spectrometer OEM

Owner of Malvern Panalytical (direct competitor in fusion)

Company Snapshot

$41.5M

Revenue

1972

Founded

Western Australia, Australia

Headquarters

SWOT Analysis

Strengths

  • Consumables profit engine: Consumables generated A$6.8m PBT at a 37.5% margin in FY2026 and 41–51% of segment PBT across FY2022–FY2026 (Note 4).
  • Margin expansion track record: gross margin rose from 41.6% (FY2023) to 49.3% (FY2026) (income statements).
  • Net cash balance sheet: net cash of A$8.5m at 30 June 2026 after funding a A$5.6m acquisition; debt only A$0.94m (FY2026 Annual Report).
  • Consistent earnings compounding: NPAT attributable CAGR of 14.6% FY2022–FY2026; record result in each of FY2023–FY2026.
  • Dividend reliability: eight consecutive years of dividend increases to FY2025, fully franked; 61% payout (FY2025–FY2026).
  • Successful bolt-on M&A: Orbis acquired at A$0.8m for 50% in FY2022 has grown to A$8.9m revenue (FY2026); Labfit integrated within one quarter.
  • Management continuity: MD has run the business since 2012, delivering market capitalisation growth from A$26.8m (30 June 2019) to A$247.5m (30 June 2026).

Weaknesses

  • Small scale: A$64.4m revenue against multinational competitors with revenues in the billions.
  • Very long cash conversion cycle: c.250 days in FY2026, with inventory at A$21.0m (27% of assets).
  • Concentrated governance: four-person board; two NEDs at 14 years' tenure; founder director paid A$255,520 in consultancy fees plus related-party rent of A$120,132 (FY2026).
  • No clawback provisions in executive reward policy (FY2026 Remuneration Report).
  • Limited disclosure: no headcount, total R&D, customer-destination geography, or formal financial guidance.
  • Thin institutional ownership and liquidity: institutions c.2.5% of register; single-broker coverage; daily volume typically 60,000–150,000 shares (mid-2026).
  • Auditor independence breaches reported in FY2025 (BDO Belgium prohibited tax-effect service; concurrence lapses), albeit immaterial (FY2025 auditor's independence declaration).

Opportunities

  • CGA revenue ramp: US$5.3m 2025 revenue base acquired for US$4m; Perth production from Dec 2026 quarter; consumables cross-sell potential.
  • India direct market: office profitable within its first full quarter (Sep 2026 qtr) in a large, growing market with a big installed base of XRF spectrometers.
  • US market: new direct office; US already c.10% of revenue; ex-Bruker US staff joined.
  • xrTGA adoption: first A$1m year with repeat orders from two large global companies (FY2026).
  • Orbis momentum: revenue +66% in the Sep 2026 quarter; new OM25 and standalone dividers; robotic cell integration.
  • Six-machine development pipeline for FY2027 and beyond.
  • Further bolt-on M&A in adjacent lab-product segments using net cash and debt capacity.

Threats

  • Mining cycle downturn reducing sample volumes and equipment capex.
  • Competitive response in CS/OHN from LECO and Eltra, with established service networks.
  • Integration risk on CGA manufacturing transfer from Germany to Perth (execution risk flagged by market commentators).
  • Platinum price spikes delaying new labware orders (observed Q2–Q3 FY2026).
  • Trade policy: tariffs affecting the c.10% US revenue share.
  • Key-person risk: founder aged mid-80s; long-tenured MD; small KMP group (two people).
  • FX translation: AUD strength reduces reported European and Canadian earnings (FX translation loss of A$0.76m in OCI in FY2026).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
15 Apr 2025March 2025 quarter: revenue A$13.9m (-9%), PBT A$3.4m (+5%); 9M revenue A$42.4m, PBT A$10.3m; Labfit integrated; US c.10% of revenueMargin resilience despite softer revenue; tariff exposure quantified
Jul 2025June 2025 quarter record PBT A$4.3mStrong exit to FY2025
18–19 Aug 2025FY2025 results: revenue A$59.5m (-1%), NPAT A$10.4m (+17%); final DPS 4.5c (+15%); revenue and EPS slightly below consensusRecord profit but flat top line; share price subsequently weakened
26 Sep 2025FY2025 final dividend paid (4.5c)Eighth consecutive annual dividend increase
Oct 2025September 2025 quarter: revenue A$15.3m (+16%); Orbis revenue doubled to A$1.4m; Capital Equipment +16% to A$5.0m; Consumables -4% to A$4.4m; next-gen xrFuse rolloutReturn to growth
20 Oct 2025AGM (Innaloo, WA): remuneration report adopted (97%); David Brown re-electedGovernance continuity
3 Nov 2025LTI performance rights granted (146,725 MD; 57,933 CFO)Routine
Dec 2025Chairman appointed director of Regal Cream ProductsAdditional external commitment
27 Jan 2026India office announced; Sanjay Mitra Country ManagerStrategic geographic expansion
18 Feb 20261H FY2026: revenue A$31.3m (+9%), PBT A$7.5m (+8%), NPAT A$5.3m (+5%), OCF A$6.4m (+44%); record PM PBT A$2.5mRecord half; shares fell from A$2.01 in following weeks
19 Feb 2026Canaccord Genuity maintains Buy, target A$2.30 (from A$2.35)Sole broker coverage
4 Mar 202647,712 ESS shares quotedRoutine
15 Apr 2026March 2026 quarter: revenue A$15.8m (+13.8%), PBT A$3.7m (+10.7%); 9M revenue A$47.0m (+10.6%), PBT A$11.2m (+8.5%)Momentum sustained
23 Apr 2026Agreement to acquire Bruker CGA businessLargest acquisition in company history
27 Apr 2026CGA acquisition completedIntegration begins
9 Jun 2026June 2026 investor presentationStrategy update
Jun 2026CGA manufacturing and engineering handover to Perth beginsExecution milestone
23 Jun 2026Change of director's interest — David BrownFounder reduced holding during FY2026 (1,000,000 shares sold)
FY2026USA office opened; platinum loans (A$0.7m) repaid; Orbis earn-out (A$0.8m) settled in sharesBalance sheet simplification
18 Aug 2026FY2026 results: revenue A$64.4m (+8%), adjusted PBT A$16.1m (+10%), statutory PBT A$15.4m (+5%), NPAT A$10.5m (+1%), OCF A$11.4m (+12%); final DPS 4.5c (flat)Record; first flat dividend in eight years
18 Aug 20262026 Corporate Governance Statement and Appendix 4G lodgedGovernance disclosure
20 Aug 2026663,221 shares quoted (vesting of rights)Minor dilution
10–11 Sep 2026Ex-dividend and record dates—
14 Sep 2026Notice of 2026 AGM lodgedAGM expected late Oct/Nov 2026
25 Sep 2026Final dividend paid; DRP shares issued—
28 Sep 2026Change of director's interest notices (Kiggins, Grimwade, Stazzonelli)DRP participation (inferred)
13 Oct 2026September 2026 quarter: revenue A$21.1m (+38%; +25% ex one-off metal sale), PBT A$4.4m (+30%); Consumables +27%; Capital Equipment +18%; Orbis +66% to A$2.4m; PM +63%; India profitableRecord September quarter (traditionally seasonally weakest)
13 Oct 2026Shares rise c.16% intraday to A$1.91Market re-rating on growth acceleration
Sep 2026 qtrOM25 crusher and Standalone RSD/LSD released; platinum lease closedProduct and balance-sheet milestones

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

5 charts
Income Statement: Revenue & Gross Profit: Total revenue rose from AUD 40 Mn in FY2022 to AUD 64.4 Mn in FY2026.
XRF Scientific Limited — Income Statement: Revenue & Gross Profit
Series (AUD Mn)FY2022FY2023FY2024FY2025FY2026
Total revenue4055.360.159.564.4
Sales revenue — external customers4055.259.859.264.1
Cost of sales22.732.333.630.732.7
Gross profit17.32326.628.831.7

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.